Screener
Ligand Pharmaceuticals LGND Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesFairValueDisclosure.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
FAQ
- What is Ligand Pharmaceuticals's total liabilities?
- Ligand Pharmaceuticals (LGND) reported total liabilities of $3.42M in Q2 2026.
- How has Ligand Pharmaceuticals's total liabilities changed year-over-year?
- Ligand Pharmaceuticals's total liabilities decreased by 97.2% year-over-year, from $120.08M to $3.42M.
- What is the long-term trend for Ligand Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's total liabilities has grown at a -65.4% compound annual growth rate (CAGR), from $652.76M to $3.22M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Ligand Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude